Luxembourg: 12 November 2022 - AML/CFT submission deadline for non-regulated alternative investment funds

In brief

On 12 October 2022, the "Administration de l'enregistrement, des domaines et de la TVA" (AED) released on its website several documents regarding the AML/CFT supervision of Luxembourg alternative investment funds (AIFs) that are not supervised by the "Commission de surveillance du secteur financier" (CSSF) ("Unregulated AIFs").

The AED requires Unregulated AIFs to do the following:

For further information on what this development might mean for you and assistance with completing the required documentation, please get in touch with your usual Baker McKenzie contact.


Key takeaways

The following documents regarding the AML/CFT supervision of Unregulated AIFs have been released on the AED's website:

  • An FAQ regarding the RR and the RC

In this FAQ, the AED requires all Unregulated AIFs to appoint the following:

  • A person from among the members of their management bodies responsible for compliance with the professional obligations as regards the fight against money laundering and terrorist financing (a "responsable du respect des obligations" or "RR").
  • If the size and nature of the activity so require, a compliance officer at the appropriate hierarchical level (a "responsable du contrôle du respect des obligations" or "RC").

The FAQ provides additional guidelines and sets forth supplementary requirements in relation to the RR and/or RC appointments.

   Unregulated AIFs must return to the AED the duly completed "AIF RC RR Identification Form" with the signed legal documentation (minutes of board meetings or circular resolutions of the governing body of the AIF acting for and on behalf of the AIF) related to any appointment of the RC and/or RR of the Unregulated AIF. The AED pointed out that this form must be transmitted without delay in case of the initial appointment or the replacement of the RC and/or RR. 

The AED also invites Unregulated AIFs, through their RR or RC to fill in and transmit the "AIF AML/CFT Questionnaire 2021" for the financial year ending in 2021 by close of business on 12 November 2022 at the latest. A dedicated guide for completion is available on the AED's website.

Copyright © 2023 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.